Enliven reports Q3 EPS (51c), consensus (47c)

As of September 30 the Company had cash, cash equivalents and marketable securities totaling $263.5M.. which is expected to provide cash runway into early 2026…”We made significant progress this past quarter,” said Sam Kintz, MBA, Enliven’s Co-founder and Chief Executive Officer. “Both of our parallel lead programs are advancing in their respective Phase 1 trials, and there continues to be strong patient demand for both trials. Our team is laser-focused on continuing to execute, and we look forward to sharing initial data for these programs next year.”